S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in

Nanobiotix Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
+0.04 (+0.24 %)
(As of 02/26/2021 04:00 PM ET)
Today's Range
Now: $16.62
50-Day Range N/A
52-Week Range N/A
Volume3,719 shs
Average Volume38,941 shs
Market Capitalization$554.11 million
P/E RatioN/A
Dividend YieldN/A
Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France.

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:NBTX
Phone33 1 40 26 04 70
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$554.11 million
Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

1.13 out of 5 stars

Medical Sector

910th out of 1,962 stocks

Biotechnology Industry

18th out of 119 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Receive NBTX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Nanobiotix (NASDAQ:NBTX) Frequently Asked Questions

Is Nanobiotix a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nanobiotix in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Nanobiotix stock.
View analyst ratings for Nanobiotix
or view top-rated stocks.

What stocks does MarketBeat like better than Nanobiotix?

Wall Street analysts have given Nanobiotix a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nanobiotix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Nanobiotix?

Nanobiotix saw a drop in short interest during the month of January. As of January 29th, there was short interest totaling 16,500 shares, a drop of 21.4% from the January 14th total of 21,000 shares. Based on an average daily trading volume, of 53,500 shares, the short-interest ratio is currently 0.3 days.
View Nanobiotix's Short Interest

Who are Nanobiotix's key executives?

Nanobiotix's management team includes the following people:
  • Mr. Laurent Levy, Co-Founder, Pres of the Exec. Board & CEO (Age 48)
  • Mr. Philippe Mauberna, CFO & Member of the Exec. Board (Age 57)
  • Ms. Anne-Juliette Hermant M.A., Chief People Officer & Member of Exec. Board (Age 48)
  • Ms. Elsa Borghi, Head of Innovation & Drug Discovery
  • Prof. Para Prasad Ph.D., Co-Founder and Member of Scientific Board (Age 76)
  • Mr. Earl J. Bergey Ph.d., Co-Founder (Age 66)
  • Mr. Alain Dostie, Chief Operating Officer
  • Ms. Noël Kurdi, Director of Investor Relations
  • Mr. Brandon Owens, VP of Strategic Marketing & Corp. Communication
  • Ms. Sarah Gaubert, Head of Communication & Public Affairs Department

Who are some of Nanobiotix's key competitors?

When did Nanobiotix IPO?

(NBTX) raised $95 million in an initial public offering on Friday, December 11th 2020. The company issued 6,500,000 shares at $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont served as the underwriters for the IPO.

What is Nanobiotix's stock symbol?

Nanobiotix trades on the NASDAQ under the ticker symbol "NBTX."

When did Nanobiotix's quiet period expire?

Nanobiotix's quiet period expired on Wednesday, January 20th. Nanobiotix had issued 7,300,000 shares in its IPO on December 11th. The total size of the offering was $98,550,000 based on an initial share price of $13.50. During Nanobiotix's quiet period, insiders and any underwriters involved in the IPO were restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who are Nanobiotix's major shareholders?

Nanobiotix's stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (4.20%), Artal Group S.A. (3.00%), Tybourne Capital Management HK Ltd. (2.25%), Orbimed Advisors LLC (1.50%) and Monashee Investment Management LLC (0.04%).

Which institutional investors are buying Nanobiotix stock?

NBTX stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Artal Group S.A., Tybourne Capital Management HK Ltd., Orbimed Advisors LLC, and Monashee Investment Management LLC.

What is Nanobiotix's stock price today?

One share of NBTX stock can currently be purchased for approximately $16.62.

How much money does Nanobiotix make?

Nanobiotix has a market capitalization of $554.11 million.

How many employees does Nanobiotix have?

Nanobiotix employs 98 workers across the globe.

What is Nanobiotix's official website?

The official website for Nanobiotix is www.nanobiotix.com.

How can I contact Nanobiotix?

The company can be reached via phone at 33 1 40 26 04 70.

This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.